Stockreport

Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities [Yahoo! Finance]

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF The stock offers a 100% upside potential at the prevailing level, as of April 23 closing, based on its 1-year median price target of $7. This supports a moderately bull [Read more]